Shigeru Kinoshita

USPTO Granted Patents = 24 (Patent Applications = 16)

CIPO Patents = 9 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Osaka, JP (2012 - 2023)
Kyoto, JP (2011 - 2024)

Company Filing History:

13 out of 49

Kyoto Prefectural Public University Corporation

patents

11 out of 228

Senju Pharmaceutical Co., Ltd.

Jcr Pharmaceuticals Co., Ltd.

Kyoto Prefetural Public University Corporation

Foundation for Biomedical Research and Innovation at Kobe

patents

15. 1 out of 281

Santen Pharmaceutical Co., Ltd.

patents

16. 6 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12072334 - Corneal endothelial cell marker (2024-08-27),

2. 11918630 - Treatment of retina and nerve using laminin (2024-03-05),

3. 11839618 - Agent for promoting corneal endothelial cell adhesion (2023-12-12),

4. 11730722 - Corneal endothelium ECM therapeutic medicaments (2023-08-22),

5. 11633477 - Treatment of cornea using laminin (2023-04-25),

6. 11633404 - Agent for promoting corneal endothelial cell adhesion (2023-04-25),

7. 11624053 - Application of laminin to corneal endothelial cell culture (2023-04-11),

8. 11479754 - Method for producing cultivated epithelial cell sheet (2022-10-25),

9. 11436719 - Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program (2022-09-06),

10. 11382904 - Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium (2022-07-12),

11. 10959997 - Combined agent for cell therapy of corneal endothelial cell (2021-03-30),

12. 10908161 - Corneal endothelial cell marker (2021-02-02),

13. 10813920 - Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage (2020-10-27),

14. 10335439 - Method for producing human corneal epithelium sheet (2019-07-02),

15. 10174284 - Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells (2019-01-08),

Certainly! Here is the article about inventor Shigeru Kinoshita:

Title: Shigeru Kinoshita: Innovating for Ophthalmological Advancements

Introduction: Shigeru Kinoshita, a distinguished inventor hailing from Kyoto, Japan, has made significant contributions to the field of ophthalmology with his innovative patents.

Latest Patents:

1. **Treatment of Retina and Nerve using Laminin:** Kinoshita's groundbreaking technique focuses on treating retinal epithelium and nerves. By utilizing laminin and its fragments, his agent offers a novel approach to address retinal diseases and ophthalmological nerve conditions.

2. **Agent for Promoting Corneal Endothelial Cell Adhesion:** Another notable invention by Kinoshita is an agent designed to enhance the adhesion of corneal endothelial cells. Through the inclusion of a Rho kinase inhibitor, this innovation paves the way for improved corneal health treatments.

Career Highlights:

Shigeru Kinoshita has showcased his expertise at renowned institutions such as the Kyoto Prefectural Public University Corporation and Senju Pharmaceutical Co., Ltd., where he has consistently pushed the boundaries of ophthalmological research and development.

Collaborations:

Throughout his career, Kinoshita has collaborated closely with esteemed professionals in the field, including Noriko Koizumi and Naoki Okumura. Together, they have synergized their efforts to drive forward cutting-edge advancements in ophthalmic care.

Conclusion:

In conclusion, Shigeru Kinoshita's relentless dedication to pioneering innovations in ophthalmology has not only expanded the realm of possibilities for treatment solutions but also exemplified the profound impact that inventors can have on improving healthcare outcomes globally.

This text is generated by artificial intelligence and may not be accurate.